Cargando…
Relaxin-2 in Cardiometabolic Diseases: Mechanisms of Action and Future Perspectives
Despite the great effort of the medical community during the last decades, cardiovascular diseases remain the leading cause of death worldwide, increasing their prevalence every year mainly due to our new way of life. In the last years, the study of new hormones implicated in the regulation of energ...
Autores principales: | Feijóo-Bandín, Sandra, Aragón-Herrera, Alana, Rodríguez-Penas, Diego, Portolés, Manuel, Roselló-Lletí, Esther, Rivera, Miguel, González-Juanatey, José R., Lago, Francisca |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5563388/ https://www.ncbi.nlm.nih.gov/pubmed/28868039 http://dx.doi.org/10.3389/fphys.2017.00599 |
Ejemplares similares
-
Relaxin-2 as a Potential Biomarker in Cardiovascular Diseases
por: Aragón-Herrera, Alana, et al.
Publicado: (2022) -
Relaxin-2 plasma levels in atrial fibrillation are linked to inflammation and oxidative stress markers
por: Aragón-Herrera, Alana, et al.
Publicado: (2022) -
Adipokines and Inflammation: Focus on Cardiovascular Diseases
por: Feijóo-Bandín, Sandra, et al.
Publicado: (2020) -
Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Regulation of Inflammatory Processes in Animal Models
por: Feijóo-Bandín, Sandra, et al.
Publicado: (2022) -
Altered MicroRNA Maturation in Ischemic Hearts: Implication of Hypoxia on XPO5 and DICER1 Dysregulation and RedoximiR State
por: Pérez-Carrillo, Lorena, et al.
Publicado: (2023)